Profile
BCLI VRTX REGN SGEN ARGX ALNY
Company Name Brainstorm Cell Therapeutics Inc. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $7.89M $128.84B $64.28B $43.15B $39.39B $33.74B
Employees 0.03K 6.10K 15.16K 3.26K 1.60K 2.23K
CEO Mr. Chaim Lebovits Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Timothy Van Hauwermeiren EMBA, M.Sc. Dr. Yvonne L. Greenstreet M.B.A., M.D.
Ratings
BCLI VRTX REGN SGEN ARGX ALNY
Quant Rating Score 2 2 4 3 3 1
Quant Rating Sell Sell Buy Neutral Neutral Strong Sell
Trading
BCLI VRTX REGN SGEN ARGX ALNY
Last Close $1.22 $429.6 $547.67 $228.74 $569.12 $258.35
High 52 $3.25 $516.74 $1201.76 $228.74 $671.75 $296.75
Low 52 $0.22 $396.64 $546.39 $228.74 $356.01 $146.93
Price vs. 52 Week High -62.46 % -16.86 % -54.43 % 0 % -15.28 % -12.94 %
Price vs. 52 Week Low 454.55 % 8.31 % 0.23 % 0 % 59.86 % 75.83 %
Total Return
BCLI VRTX REGN SGEN ARGX ALNY
1 Month Return 9.47 % -10.93 % -4.95 % 0 % 0.94 % 6.21 %
3 Month Return -28.78 % -8.46 % -22.81 % 0 % -11.99 % -6.46 %
6 Month Return 1.67 % -16.86 % -33.89 % 0 % -4.51 % -6.88 %
9 Month Return 371.04 % -8.29 % -51.59 % 0 % 6.38 % -4.14 %
YTD Return -46.26 % 6.68 % -23.12 % 0 % -7.46 % 9.79 %
1 Year Return 161.24 % 2.53 % -43.42 % 0 % 48.77 % 70.67 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
BCLI VRTX REGN SGEN ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.15 % - - -
Dividend Paid and Capex Coverage Ration (TTM) -5.4 % -1.65 % 3.85 % -2.27 % -44.32 % -1.49 %
Dividend Per Share (TTM) - - 0.88 % - - -
Payout Ratio (TTM) - - 2.08 % - - -
Growth
BCLI VRTX REGN SGEN ARGX ALNY
Asset Growth -56.46 % -0.87 % -1.21 %
Gross Profit Growth 420.38 % 10.25 % 22.93 %
Revenue Growth - 11.66 % 24.65 %
Revenue 3 Year - 45.6 % 91.56 %
Revenue 5 Year 1057.01 % 163.93 % 215.48 %
Revenue 10 Year - 1632.15 % 494.04 %
EBIT Growth 100 % -93.69 % 10.13 %
Net Income Growth 167.61 % -114.8 % 9.51 %
Net Income 3 Yeari Growth Per Share 423.84 % -122.89 % -763.59 %
Net Income 5 Yeari Growth Per Share 306.22 % -145.38 % -276.93 %
Net Income 10 Yeari Growth Per Share 423.46 % 33.84 % -624.16 %
Operating Income Growth 100 % -105.41 % 10.13 %
Operating Cash Flow Growth (CFG) 55.55 % -113.93 % 9.07 %
Operating 3 Year CFG -135.91 % -118.65 % -147.99 %
Operating 5 Year CFG -233.55 % -131.3 % -195.86 %
Operating 10 Year CFG -421.45 % 12.43 % -2622.09 %
EPS Growth 647.5 % -114.8 % 10.81 %
EPS Diluted Growth 647.5 % -114.97 % 10.81 %
Book Value Per Share -1193.65 % -6.59 % -9.83 %
Share Holder 3 Year Equity Growth Per Share -373.52 % 62.6 % 33.72 %
Share Holder 5 Year Equity Growth Per Share -162.06 % 168.85 % 220.81 %
Share Holder 10 Year Equity Growth Per Share -399.29 % 1265.7 % 691.19 %
Dividend Per Share Growth - - -
Dividend 3 Year Growth Per Share - - -
Dividend 5 Year Growth Per Share - - -
Dividend 10 Year Growth Per Share - - -
Debt Growth 7.14 % 116.42 % -23.28 %
Free Cash Flow Growth -44308.09 % -124.1 % 3.67 %
Updated On 31 Dec 2024 31 Dec 2024 31 Dec 2022
Profitability
BCLI VRTX REGN SGEN ARGX ALNY
Gross Profit Margin TTM - 86.09 % 84.94 % 72.37 % 46.33 % 86.01 %
Return on Assets TTM -634.44 % -2.38 % 11.98 % -11.76 % 13.45 % -6.4 %
Return on Equity TTM 203.04 % -3.28 % 14.77 % -16.53 % 16.83 % -509.33 %
Return on Capital Employed TTM 163.63 % -1.3 % 11.35 % -16.87 % -0.31 % -3.68 %
Net Income Per EBT TTM 100 % -215.53 % 90.27 % 100.55 % 25990.14 % 75.89 %
EBT Per Ebit TTM 99.4 % -100.69 % 129.3 % 94.01 % -18.79 % 308.03 %
EBIT Per Revenue TTM - -2.24 % 27.37 % -36.09 % -0.77 % -4.91 %
Cash Flow To Debt Ratio TTM -1262.92 % -28.16 % 146.15 % -185.98 % -201.37 % -3.47 %
Receivables Turnover TTM - 6.84 2.53 1.98 2.46 5.62
Payables Turnover TTM 0.01 3.71 3.01 1.54 1.83 3.37
Inventory Turnover TTM - 1.27 0.66 0.65 2.93 5.01
Fixed Asset Turnover TTM - 425.82 % 300.07 % 256.83 % 5106.8 % 337.41 %
Asset Turnover TTM - 48.84 % 37.52 % 34.46 % 35.83 % 55.72 %
Operating Cash Flow Per Share TTM -1.48 -1.91 37.05 -1.12 -1.07 -0.35
Free Cash Flow Per Share TTM -1.48 -3.07 28.3 -1.62 -1.09 -0.58
Cash Per Share TTM 3.04 % 2375.11 % 7825.12 % 657.5 % 4597.04 % 2024.29 %
Operating Cash Flow Sales Ratio TTM - -4.48 % 28.06 % -16.85 % -3.54 % -1.92 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 160.43 % 76.4 % 144.14 % 102.26 % 167.11 %
Cash Flow Coverage Ratios TTM -1262.92 % -28.16 % 146.15 % -185.98 % -201.37 % -3.47 %
Price To Free Cash Flows Ratio TTM -0.87 -163.02 21.29 -141.85 -505.86 -447.57
Price To Operating Cash Flows Ratio TTM -0.82 -261.97 16.35 -203.89 -601.06 -745.64
Price Cash Flow Ratio TTM -0.82 -261.97 16.35 -203.89 -601.06 -745.64
Income Statement (TTM)
BCLI VRTX REGN SGEN ARGX ALNY
Revenue $0B $11.02B $14.2B $1.96B $2.19B $2.25B
Gross Profit $0B $9.49B $12.23B $1.55B $1.96B $1.92B
Gross Profit Ratio 100% 86.11% 86.13% 79.1% 89.62% 85.62%
EBITDA $0B $0.48B $5.32B $-0.62B $0B $-0.18B
Net Income $0.01B $-0.54B $4.41B $-0.61B $0.83B $-0.28B
EPS Diluted 2.19 -2.08 38.34 -3.3 12.78 -2.16
Balance Sheet (MRQ)
BCLI VRTX REGN SGEN ARGX ALNY
Long Term Debt $0B $1.66B $1.98B $0.04B $0.03B $0B
Total Liabilities $0.01B $6.12B $8.41B $0.87B $0.7B $4.17B
Total Equity $-0.01B $16.41B $29.35B $2.8B $5.5B $0.07B
Total Investments $0B $6.65B $15.42B $1.42B $1.93B $1.73B
Total Debt $0B $1.75B $2.7B $0.04B $0.04B $1.3B
Total Assets $0B $22.53B $37.76B $3.67B $6.2B $4.3B
Cash Flow Statement (TTM)
BCLI VRTX REGN SGEN ARGX ALNY
Net Income $-0.01B $-0.54B $4.41B $-0.61B $0.8B $-0.28B
Inventory $0B $-0.52B $-0.62B $-0.23B $-0.09B $0.01B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $-0.49B $4.42B $-0.45B $-0.08B $-0.01B
Capital Expenditure $0B $-0.3B $-0.76B $-0.08B $-0.07B $-0.03B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 24.375
ABCL AbCellera Biologics Inc. 2.04
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.405
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.0035
ABPWW 0.02
ABSI Absci Corporation 2.75
ABUS Arbutus Biopharma Corporation 3.295
ABVC ABVC BioPharma, Inc. 1.28
ABVX Abivax SA American Depositary Shares 6.76
ACAD ACADIA Pharmaceuticals Inc. 17.33
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.5957
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 2.42
ACIU AC Immune SA 1.68
ACLX Arcellx, Inc. 56.01
ETFs With Exposure to BCLI
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 278.505
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00006 123.64
VXF Vanguard Extended Market Index Fund 0 177.295
IWC iShares Micro-Cap ETF 0.00458 114.525
VITNX Vanguard Institutional Total Stock Market Index Fund Institutional Shares 0 94.59
VITPX Vanguard Institutional Total Stock Market Index Fund Institutional Plus Shares 0 94.58
STSB iShares Factors US Small Blend Style ETF 0.02 22.13
VTSAX Vanguard Total Stock Market Index Fund 0 135.4
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 134.56
VITSX Vanguard Total Stock Market Index Fund 0 135.42
SWTSX Schwab Total Stock Market Index Fd Select Shs a Series of Schwab Capit 0.000106985 95.44
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 134.57
AVSC Avantis U.S. Small Cap Equity ETF 0 48.405
VEMPX Vanguard Extended Market Index InstlPlus 0 332.06
VSMPX Vanguard Total Stock Mkt Idx Instl Pls 0 254.04
Unlock